coenzyme-q10 and tocophersolan

To evaluate the postoperative effects of topical coenzyme Q(10) + vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate (CoQ(10)) after cataract surgery.. 40 consecutive patients were randomized to receive CoQ(10) or saline solution (SS) twice daily for 9 months after uneventful cataract surgery with a temporal port. Before surgery, on day 14 and at months 3, 6 and 9, they underwent non-invasive break-up time (NIBUT) testing, Schirmer test, BUT, aesthesiometry as well as in vivo confocal microscopy of the subbasal nerve plexus of the cornea (SBP). The density of the subbasal nerves was calculated in the central (CFD) and temporal (TFD) cornea (number of fibres per field).. On day 14, surgery reduced CFD and TFD, respectively, by 25-35 and 50%; indices of ocular surface stability were all impaired. The treatment with CoQ(10) was associated with faster nerve regeneration than SS (at month 3, CFD +1.5 ± 1.9 vs. +0.2 ± 1.8, p = 0.04, and TFD +2.5 ± 1.7 vs. +1.0 ± 1.6, p = 0.007; at month 6, TFD +2.7 ± 1.9 vs. +1.4 ± 1.5, p = 0.02) and better stability of ocular surface (NIBUT and BUT) throughout the study. No relevant side effects were found, apart from occasional burning in 10% of CoQ(10) patients.. Changes of the corneal nerves occurring after cataract surgery may influence the integrity of the ocular surface. Treatment with topical CoQ(10) has a positive effect in restoring SBP anatomy and ocular surface stability.

Topics: Administration, Topical; Aged; Cataract Extraction; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microscopy, Confocal; Ophthalmic Solutions; Polyethylene Glycols; Postoperative Care; Postoperative Complications; Retrospective Studies; Treatment Outcome; Ubiquinone; Vitamin E; Vitamins; Wound Healing

We aimed to create a mechanical optic nerve damage model in rats and to investigate the neuroprotective effects of topical Coenzyme Q10 + Vitamin E TPGS (CoQ10+Vit E) molecule on retinal ganglion cells. In our study, 30 eyes of 20 male Wistar rats were used. Three groups, each consisting of 10 eyes, were formed as control, experimental, and treatment groups. The control group was used to test the formation of optic nerve damage. Topical CoQ10 + Vit E TPGS solution was applied to the rats in the treatment group, one drop twice a day for 3 weeks. On the other hand, physiological drops were applied to the experimental group 2 times a day for 3 weeks. After 3 weeks, the optic nerves of the rats were dissected and examined histopathologically. In electron microscopic examination of the treatment group, it was noted that the myelin sheath in the majority of myelinated nerve fibers and the normal structures of mitochondria, neurotubules, and neurofilaments in the axoplasm were preserved. It was observed that the oligodendrocytes surrounded the myelinated axons. In the experimental group, significant degenerative changes were observed in myelinated nerve fibers in many areas. The number of myelinated axons was significantly increased in the treatment group compared to the experimental group (p = .0028). In the light of the data obtained, the neuroprotective effect of the topically used CoQ10 + Vit E TPGS molecule was found to be histopathologically effective in our experimental study.

Topics: Animals; Disease Models, Animal; Male; Optic Neuropathy, Ischemic; Rats; Rats, Wistar; Ubiquinone; Vitamin E

A prospective, open-label study in 20 professional swimmers evaluated the efficacy and safety of an ophthalmic solution containing crosslinked hyaluronic acid, coenzyme Q10, and vitamin E TPGS in releasing eye irritation and restoring ocular surface damages after prolonged exposure to chlorinated water.. Individually, one eye was instilled with the ophthalmic solution and the other used as a comparator. Eye drops were self-administered three times a day for 2 months. Tear film breakup time (primary endpoint), Schirmer I test, beating of eyelashes/min, tear osmolarity, corneal and conjunctival staining with fluorescein, Ocular Surface Disease Index questionnaire, subject satisfaction, visual acuity (secondary endpoints), and Efron Grading Scale were evaluated at screening/baseline (V1), week 1 (V2), week 2 (V3), week 4 (V4), and week 8 (V5).. After 2 months, breakup time test significantly improved in the treated eyes (+1.67 s) compared to control (-3.00 s) (. The adequate combination of crosslinked hyaluronic acid, coenzyme Q10, and vitamin E TPGS, contained in the ophthalmic solution VisuXL

Topics: Administration, Ophthalmic; Adolescent; Adult; Chloramines; Conjunctival Diseases; Corneal Diseases; Cross-Linking Reagents; Disinfectants; Drug Combinations; Humans; Hyaluronic Acid; Hyperemia; Male; Ophthalmic Solutions; Osmolar Concentration; Prospective Studies; Quality of Life; Surveys and Questionnaires; Swimming Pools; Tears; Ubiquinone; Vitamin E; Vitamins; Water Pollutants, Chemical; Young Adult

The tocopherol-based excipient, TPM, when incorporated into a medium-chain triglyceride (MCT)-based lipid formulation, has been previously shown to improve the solubilization of Coenzyme Q10 (CoQ10) during in vitro digestion which is strongly correlated with enhanced exposure in vivo.. The current study aimed to gain further understanding of the MCT + TPM co-formulation, by assessing the formulation performance under fasted and fed in vitro digestion conditions, with different drug and excipient loading levels. Natural and synthetic-derived TPM were equivalent, and with d-α- tocopherol polyethylene glycol 1000 succinate (TPGS) outperformed other derivatives in enhancing the solubilisation of CoQ10 during digestion.. Fed conditions significantly improved the solubility of CoQ10 during in vitro digestion of the formulation in comparison with fasted conditions. The addition of TPM at 10% (w/w) of the total MCT + TPM provided optimal performance in terms of CoQ10 solubilization during digestion.. The results further highlights the potential of TPM as an additive in lipid formulations to improve the solubilization and oral bioavailability of poorly water-soluble compounds.

Topics: Digestion; Excipients; Fasting; Intestine, Small; Phosphorylation; Solubility; Triglycerides; Ubiquinone; Vitamin E

Coenzyme Q

Topics: A549 Cells; Aerosols; Antioxidants; Biological Transport; Calibration; Cell Survival; Chemistry, Pharmaceutical; Drug Delivery Systems; Drug Liberation; Drug Stability; Humans; Lecithins; Lung; Nanoparticles; Nebulizers and Vaporizers; Particle Size; Stearates; Surface Properties; Ubiquinone; Viscosity; Vitamin E

Coenzyme Q10 (CoQ10) is a mitochondrial-targeted antioxidant with known neuroprotective activity. Its ocular effects when co-solubilised with α-tocopherol polyethylene glycol succinate (TPGS) were evaluated. In vitro studies confirmed that CoQ10 was significantly protective in different retinal ganglion cell (RGC) models. In vivo studies in Adult Dark Agouti (DA) rats with unilateral surgically-induced ocular hypertension (OHT) treated with either CoQ10/TPGS micelles or TPGS vehicle twice daily for three weeks were performed, following which retinal cell health was assessed in vivo using DARC (Detection of Apoptotic Retinal Cells) and post-mortem with Brn3a histological assessment on whole retinal mounts. CoQ10/TPGS showed a significant neuroprotective effect compared to control with DARC (p<0.05) and Brn3 (p<0.01). Topical CoQ10 appears an effective therapy preventing RGC apoptosis and loss in glaucoma-related models.

Topics: Animals; Disease Models, Animal; Male; Mitochondria; Neuroprotection; Neuroprotective Agents; Ocular Hypertension; Rats; Retinal Ganglion Cells; Treatment Outcome; Ubiquinone; Vitamin E

This study aimed to design the chitosan coated TPGS liposome to enhance the bioavailability of Coenzyme Q10 (CoQ10). Optimization of formulation variables for the preparation of the liposome was performed and then three liposomal formulations (TPGS-liposome, TPGS-chitosome, chitosome) were prepared with narrow size distribution and high encapsulation efficiency. All of three liposomal formulations were stable at pH 1.2 and 7.0 for 24h without any significant drug leakage. Furthermore, chitosan-coated liposomes showed the strong mucoadhesive properties. All the tested liposomal formulations significantly enhanced the cellular uptake of CoQ10 as compared to the untreated drug. Particularly, TPGS-chitosome appeared to be most effective in improving the cellular uptake of CoQ10 in Caco-2 cells (about 30-folds greater than the untreated powder formulation). In oral pharmacokinetic studies, TPGS-chitosome enhanced the systemic exposure of CoQ10 by 3.4 folds as compared to the untreated powder and also displayed the extended drug release profile for up to 24h in rats. Compared to the untreated powder CoQ10, TPGS-chitosome significantly improved the antioxidant effect of CoQ10 and reduced the intracellular ROS level. In conclusion, TPGS-chitosome significantly enhanced the oral bioavailability of CoQ10 and prolonged drug release profile in rats, suggesting that TPGS-chitosome could be an effective oral delivery platform to improve the oral bioavailability of poorly absorbable drugs.

Topics: Administration, Oral; Animals; Antioxidants; Biological Availability; Caco-2 Cells; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Drug Delivery Systems; Humans; Liposomes; Male; Particle Size; Polyethylene Glycols; Powders; Rats; Rats, Sprague-Dawley; Ubiquinone; Vitamin E